Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $1.6M rose 68.7% year over year, behind the +74.8% change in trailing-twelve-month gross profit. Sequentially, it fell 23.7% from the prior quarter. Over 3 fiscal years it compounded at -31.4% a year.

Context

  • Gross profit amounted to 73.3% of revenue in FY2025, down 11.8 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +68.7% toward the trailing-twelve-month pace of +74.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.6M-23.7% QoQ
Last fiscal yearDec 2025
$5.74M-64.0% YoY
LTMMar 2026
$6.39M+74.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+68.7%——
1 year-64.0%——
3-year CAGR-31.4%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
5.74M USD
Year-over-year change
-64.0%
4-year CAGR
+29.4%

Gross Profit vs competitors

How ACRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +74.8% is the 3rd highest of 8, against a peer median of +8.4%.
  • Gross profit amounts to 76.3% of revenue for ACRS, versus a peer median of 102.3%.
ACRS Competitors
Gross Profit for ACRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$270.54M USD+582.2%—116.4%
ALMSAlumis Inc. Common StockLTM Jun 2026$6.53M USD-66.1%—88.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$6.39M USD+74.8%-31.4%76.3%
ATTOAttovia Therapeutics, Inc.FY2025$546K USD+274.4%—40.4%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€0 EUR———
IMUXImmunic, Inc.LTM Mar 2026-$33K USD+50.0%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$66.6K USD———
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$2.34M USD-7090.5%——
IFRXInflaRx N.V.LTM Mar 2026-€7.23M EUR-142.9%—24646.3%
TRAXFirst Tracks Biotherapeutics IncFY2025-$139.61M USD+8.4%——
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ACRS) —+8.4%—102.3%

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.76M29.75M31.25M18.72M7.83M
Cost of Revenue4.71M11.96M18.08M2.79M2.09M
Gross Profit2.05M17.79M13.17M15.93M5.74M
Gross Margin30.3%59.8%42.1%85.1%73.3%
Research & Development43.81M77.81M98.38M33.59M52.65M
Selling, General & Admin23.62M25.13M31.1M22.2M21.97M
Operating Expenses91.77M107.65M110.53M157.86M82.11M
Depreciation & Amortization923K797K863K807K454K
EBITDA(64.46M)(84.36M)(115.45M)(51.72M)(64.47M)
EBITDA Margin-953.4%-283.5%-369.5%-276.3%-823.8%
Operating Income(89.72M)(89.85M)(97.36M)(141.93M)(76.38M)
Operating Margin-1327.1%-302.0%-311.6%-758.2%-975.9%
Interest Income0007.95M7.64M
Interest Expense00000
Other Income / Expenses(1.14M)2.95M8.51M9.87M11.45M
Income Before Tax(90.87M)(86.91M)(88.85M)(132.07M)(64.92M)
Pre-Tax Margin-1344.0%-292.1%-284.3%-705.5%-829.6%
Income Tax Expense00(367K)00
Net Income(90.87M)(86.91M)(88.48M)(132.07M)(64.92M)
Net Margin-1344.0%-292.1%-283.1%-705.5%-829.6%
EPS (Basic)(1.60)(1.33)(1.27)(1.71)(0.53)
EPS (Diluted)(1.60)(1.33)(1.27)(1.71)(0.53)
Weighted Avg Shares56.73M65.21M69.81M77.3M122.66M
Weighted Avg Shares (Diluted)56.73M65.21M69.81M77.3M122.66M

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.